Anthos to stop factor XI trial in atrial fibrillation early after 'overwhelming benefit'
Anthos Therapeutics announced Monday morning that it is stopping a Phase II study of its next-generation anticoagulant abelacimab in atrial fibrillation as a result of “overwhelming benefit.”
The decision came after an independent data monitoring committee recommended the company and its academic collaborator — the TIMI Study Group from Brigham and Women’s Hospital and Harvard — to stop the study early since patients in the treatment arm saw a substantial reduction in bleeding events compared to those in the control arm, who received Johnson & Johnson’s Xarelto.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.